$13.8m in Series B Funding for NovaMed is Led by Fidelity Asia Ventures and Fidelity Biosciences

$13.8m in Series B Funding for NovaMed is Led by Fidelity Asia Ventures and Fidelity Biosciences
Tuesday January 22

Investment signals confidence in NovaMed's business model and investor enthusiasm for China's growing pharmaceutical industry

SHANGHAI, China, Jan. 22 -- $13.8 Million in a Series B round of funding was awarded today to NovaMed Pharmaceuticals Inc., bringing the total raised in one year to nearly $20 Million. The fund was led by the newly involved investors, Fidelity Asia Ventures and its US affiliate, Fidelity Biosciences, with participation from returning investor Atlas Venture.

"Series B funding marks a significant milestone in NovaMed's business development in China," says Mark Lotter, CEO and Co-Founder of NovaMed. "It allows us to continually expand and strengthen our portfolio in a number of important therapeutic areas while playing an increasingly stronger role in China's drug development landscape."

NovaMed is a China-based provider of outsourced development and commercialization services for leading global and local pharmaceutical and biotechnology companies. The company will use the proceeds from Series B funding to finance the in-licensing of new molecules for China, expand sales and distribution operations and strengthen medical research and development capacity.

"NovaMed has continued to demonstrate effective execution capabilities through in-licensing of further programs from multinationals," says Zina Affas, Principal at Atlas Venture, an investor in NovaMed. "The rapid raising of a Series B investment following our Series A investment in May 2007 demonstrates our strong belief in the capabilities of the team and the potential of the company to develop and deliver products to the Chinese market."

China is today's foremost target for global drug development and commercial growth, with a predicted 16.3% annual growth rate -- overtaking the country's overall healthcare spending. NovaMed's unique business model allows international drug brands to realize both significant cost advantages and the full potential of China's pharmaceutical market. The Series B funding reflects global investors' increased excitement and recognition over the growth potential of the China market.

"Fidelity Asia Ventures and Fidelity Biosciences are delighted to have the opportunity to invest in NovaMed, whom we see as the leader in the China specialty pharmaceutical industry," says Norman Chen, Partner at Fidelity Asia Ventures. "We look forward to utilizing our global life sciences expertise to further refine and develop NovaMed's platform of high-quality, proprietary drugs for China and in bringing this exciting business to its next stage of development."

"We are very excited to move forward with this outstanding team," says Bo Shao, Chairman and Co-Founder of NovaMed. "We are confident that with our unique approach and the valuable guidance of our investment partners, NovaMed will sustain its rapid growth in 2008 and continue to lead and drive development of the specialty pharmaceutical industry in China."

NovaMed already offers a broad range of services to international pharmaceutical and biotechnology firms in China, including facilitating the outsourcing of clinical research to China, registering unique and new chemical entities for the China market and commercializing and distributing products for multinationals in China. Over just the past few months, the company has entered into a number of strategic alliances with multinational pharmaceutical companies in China including Sanofi-Aventis, Baxter and Meda. These collaborations have expanded and strengthened the company's product lines in oncology, diabetes, respiratory, urology and central nervous system diseases. NovaMed's services for pharmaceutical multinationals, supported by a network of best-in-class research, development, regulatory, and distribution partners in China, work to accelerate the drug development and approval processes of Western-based drugs to benefit China's patients and medical professionals.

"The enthusiasm and interest from our new and existing investors," says Lotter, "represents a strong vote of confidence in our strategic and unique approach to China's fast-growing pharmaceutical market."

ABOUT NOVAMED

NovaMed Pharmaceuticals was founded in August 2005 to provide one-stop- shop service for global pharmaceutical companies and brand owners looking to leverage cost advantage and achieve optimal market potential in China. Through a directly managed sales organization of 300 people strong and growing and an exclusive network of best-in-class research, development, regulatory and distribution partners, NovaMed has built viable commercialization models for products at different stages of their life cycle. These include products already commercially available in China, internationally approved products not yet registered in China, and in-license late stage development compounds. For more information, visit www.novamed.com.cn.

ABOUT ATLAS VENTURE

Atlas Venture is a leading early-stage international venture capital firm that invests in technology and life sciences businesses in the U.S., Europe and Asia. Since inception in 1980, its partners have helped build over 300 companies in more than 15 different countries. Since 1990, 44 portfolio companies have been acquired and 40 are now public companies with an aggregate market capitalization of over $12 billion. Atlas Venture is currently investing from its seventh fund and manages over $2.5 billion in capital through offices in Boston, London, Munich, and Paris. Atlas Venture's life sciences team has been an early investor in close to 100 biotechnology, pharmaceutical and medical device companies. The active portfolio comprises approximately thirty-five life sciences companies today and several new investments are made each year, from seed stage to pre-IPO stage. Atlas Venture's past life sciences investments include companies such as Actelion Pharmaceuticals; Alnylam Pharmaceuticals; Crucell; deCODE genetics; Exelixis; Momenta; MorphoSys; Newron and Renovo. For more information, visit www.atlasventure.com.

ABOUT FIDELITY ASIA VENTURES

Fidelity Asia Ventures (FAV) is the Asian venture and growth capital arm of Fidelity International Ltd. (FIL), a part of the global Fidelity investment organization. FAV is among the earliest and most successful institutional investors in private, growth companies in China and has actively invested predominantly FIL proprietary capital in both the information technology and healthcare sectors throughout Asia for nearly 14 years, with a longstanding focus on China. More recently it has established a substantial capital pool for investment in growing private companies in India. FAV's current mission is to invest principally in high-quality, high-growth companies broadly in the information technology, healthcare and consumer sectors in China and India. FAV's investment teams in Hong Kong, Beijing, Shanghai and Mumbai are among the most experienced in the Asia-Pacific region. Current investments and recent exits include: Alibaba Holdings, Pharmanex (Acquired by Nu Skin), Wuxi PharmaTech, Hurray!, Linktone, AsiaInfo, Dianji Technology, CDP, Datuu, Xunlei, Isoftstone and Asia Renal Care (acquired by Bumrungrad International). For more information, please visit: http://www.fidelityasiaventures.com.

ABOUT FIDELITY BIOSCIENCES

Fidelity Biosciences invests venture capital in private biopharmaceutical and medical technology companies. We are a division of Fidelity Investments, one of the world's leading providers of financial services. For more than 30 years, Fidelity Investments has been a significant presence in the venture capital and private equity industry, investing the firm's own capital since 1969. This provides us with the flexibility and capabilities of traditional venture capital firms while eliminating the additional pressures of fundraising. The result is a clear focus on building long-term value for Fidelity, our management partners, and co-investors. We are engaged investors and board members, seeking to add value by providing strategic guidance and assistance to management throughout the process of building successful businesses. We possess the energy and entrepreneurial spirit of a start-up enterprise, while bringing to bear the considerable strengths and resources of Fidelity Investments. For more information, please visit: http://www.fidelitybiosciences.com.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.